Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115438

Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats.

L Massacesi, E Castigli, M Vergelli, J Olivotto, A L Abbamondi, F Sarlo, and L Amaducci

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Massacesi, L. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Castigli, E. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Vergelli, M. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Olivotto, J. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Abbamondi, A. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Sarlo, F. in: JCI | PubMed | Google Scholar

Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Florence, Italy.

Find articles by Amaducci, L. in: JCI | PubMed | Google Scholar

Published October 1, 1991 - More info

Published in Volume 88, Issue 4 on October 1, 1991
J Clin Invest. 1991;88(4):1331–1337. https://doi.org/10.1172/JCI115438.
© 1991 The American Society for Clinical Investigation
Published October 1, 1991 - Version history
View PDF
Abstract

Some activities of retinoids on cellular and humoral immunity have been described, but the available data are conflicting or obtained at concentrations that are toxic in vivo. In this study, we demonstrate that 13-cis-retinoic acid (13-cRA), a retinoid well tolerated in human therapy, can suppress T cell-mediated immunity in rats. Treatment with pharmacological concentrations of 13-cRA prevented active as well as passive transfer experimental autoimmune encephalomyelitis (EAE) and suppressed lymphocyte responsiveness to T cell mitogens, suggesting that the drug activity included suppression of an effector T cell response. In addition, mitogen- and antigen-induced lymphocyte proliferation was inhibited in vitro in the presence of concentrations of 13-cRA equivalent to or less than those achieved in vivo, further suggesting that the prevention of EAE was due to a suppressive activity on T cell-mediated immunity. The immunosuppressive activity of 13-cRA included suppression of interleukin 2, whose production was inhibited in splenocytes. These data indicate that, in an in vivo mammalian system, 13-cRA exerts a suppressive activity on T cell-mediated immunity intensive enough to suppress an ongoing immune response, and that this effect can be achieved at nontoxic concentrations that may also be attained in human therapy.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1331
page 1331
icon of scanned page 1332
page 1332
icon of scanned page 1333
page 1333
icon of scanned page 1334
page 1334
icon of scanned page 1335
page 1335
icon of scanned page 1336
page 1336
icon of scanned page 1337
page 1337
Version history
  • Version 1 (October 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts